Skadden, Kirkland advise on Chinese biotech firm’s $451 million HK IPO
BY Aparna Sai |
Skadden, Arps, Slate, Meagher & Flom and Zhong Lun Law Firm have advised China’s Everest Medicines on its $451 million IPO in Hong Kong, with Kirkland & Ellis and Tian Yuan Law Firm advising the joint sponsors and underwriters.